Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26025895 | 0.78 | — | — | |
| SCHEMBL1796245 | 0.78 | — | — | |
| SCHEMBL10760994 | 0.78 | ALDH1A1 (0.35) | KDM4EALDH1A1TSHRGAA | |
| SCHEMBL18551482 | 0.77 | KDM4E (0.31) | KDM4E | |
| SCHEMBL19978001 | 0.77 | ALDH1A1 (0.33) | KDM4EALDH1A1TSHRGAA | |
| SCHEMBL947082 | 0.75 | TSHR (0.48) | CYP1A2CYP2C19ALDH1A1TSHR | |
| SCHEMBL22224038 | 0.74 | ALDH1A1 (0.48) | KDM4ECYP1A2CYP2D6MAPK1CYP2C19 | |
| SCHEMBL19075314 | 0.74 | ALDH1A1 (0.48) | KDM4ECYP1A2CYP2D6MAPK1CYP2C19 | |
| SCHEMBL211599 | 0.73 | — | — | |
| SCHEMBL948108 | 0.72 | TSHR (0.50) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833170-B2 | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230248757-A1 | Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive Blocking | SCOTT, JOHN KIM, JR. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248757-A1 | Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive Blocking | CD209, FUT6, SIGLEC7 | KDM4E 3743/4885CYP1A2 4885/4885CYP2D6 3814/4885 |
| US-11833170-B2 | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking | CD209, FUT6, SIGLEC7 | KDM4E 3743/4885CYP1A2 4885/4885CYP2D6 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.